000132475 001__ 132475
000132475 005__ 20240229105018.0
000132475 0247_ $$2doi$$a10.1038/leu.2017.211
000132475 0247_ $$2pmid$$apmid:28761118
000132475 0247_ $$2ISSN$$a0887-6924
000132475 0247_ $$2ISSN$$a1476-5551
000132475 0247_ $$2altmetric$$aaltmetric:23398967
000132475 037__ $$aDKFZ-2018-00163
000132475 041__ $$aeng
000132475 082__ $$a610
000132475 1001_ $$0P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aGoldschmidt, Hartmut$$b0
000132475 245__ $$aBortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
000132475 260__ $$aBasingstoke$$bNature Publ. Group$$c2018
000132475 3367_ $$2DRIVER$$aarticle
000132475 3367_ $$2DataCite$$aOutput Types/Journal article
000132475 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1565604031_547
000132475 3367_ $$2BibTeX$$aARTICLE
000132475 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132475 3367_ $$00$$2EndNote$$aJournal Article
000132475 520__ $$aThe Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95% confidence interval (95% CI) of 0.65-0.89, P=0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR=0.89, 95% CI: 0.74-1.08, P=0.24). The incidence of SPM were similar between the two arms (7% each, P=0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size ⩾10%) and renal impairment at baseline (serum creatinine >2 mg dl-1) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR=1.02, P=0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.
000132475 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132475 588__ $$aDataset connected to CrossRef, PubMed,
000132475 7001_ $$aLokhorst, H. M.$$b1
000132475 7001_ $$aMai, E. K.$$b2
000132475 7001_ $$avan der Holt, B.$$b3
000132475 7001_ $$aBlau, I. W.$$b4
000132475 7001_ $$aZweegman, S.$$b5
000132475 7001_ $$aWeisel, K. C.$$b6
000132475 7001_ $$aVellenga, E.$$b7
000132475 7001_ $$aPfreundschuh, M.$$b8
000132475 7001_ $$aKersten, M. J.$$b9
000132475 7001_ $$aScheid, C.$$b10
000132475 7001_ $$aCroockewit, S.$$b11
000132475 7001_ $$aRaymakers, R.$$b12
000132475 7001_ $$aHose, D.$$b13
000132475 7001_ $$aPotamianou, A.$$b14
000132475 7001_ $$aJauch, A.$$b15
000132475 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, J.$$b16
000132475 7001_ $$aStevens-Kroef, M.$$b17
000132475 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, M. S.$$b18
000132475 7001_ $$aBroijl, A.$$b19
000132475 7001_ $$aLindemann, H. W.$$b20
000132475 7001_ $$aBos, G. M. J.$$b21
000132475 7001_ $$aBrossart, P.$$b22
000132475 7001_ $$avan Marwijk Kooy, M.$$b23
000132475 7001_ $$aYpma, P.$$b24
000132475 7001_ $$aDuehrsen, U.$$b25
000132475 7001_ $$aSchaafsma, R. M.$$b26
000132475 7001_ $$aBertsch, U.$$b27
000132475 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b28$$udkfz
000132475 7001_ $$aJarari, Le$$b29
000132475 7001_ $$aSalwender, H. J.$$b30
000132475 7001_ $$aSonneveld, P.$$b31
000132475 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/leu.2017.211$$gVol. 32, no. 2, p. 383 - 390$$n2$$p383 - 390$$tLeukemia$$v32$$x1476-5551$$y2018
000132475 909CO $$ooai:inrepo02.dkfz.de:132475$$pVDB
000132475 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aExternal Institute$$b0$$kExtern
000132475 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aExternal Institute$$b16$$kExtern
000132475 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aExternal Institute$$b18$$kExtern
000132475 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000132475 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132475 9141_ $$y2018
000132475 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132475 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132475 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2015
000132475 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132475 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132475 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132475 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132475 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132475 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132475 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132475 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132475 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132475 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2015
000132475 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000132475 980__ $$ajournal
000132475 980__ $$aVDB
000132475 980__ $$aI:(DE-He78)C060-20160331
000132475 980__ $$aUNRESTRICTED